Prescription ID | TCMF511 |
Pinyin Name | Xuan Mai Gan Ju Han Pian |
Chinese Name | 玄麦甘桔含片 |
English Name | Xuan Mai Gan Ju Han Tablet |
Function Description | 阴虚火旺, 虚火上浮, 口鼻干燥, 咽喉肿痛 |
Indications | Tonsillitis, Laryngitis |
Disease ICD-11 Category |
CA0Z [Upper respiratory tract disorders, unspecified, 上呼吸道疾患,未特指的
]; CA05 [Acute laryngitis or tracheitis, 急性喉炎或气管炎 ]; |
Human Tissues Associated with Indication | Nose, Lung |
Reference | Chinese pharmacopoeia (2015) |
Reference Book/link | ISBN 978-7-5067-7337-9 |
Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
---|---|---|---|---|
TCMH2343 | Scrophularia ningpoensis | 玄参 | TCMH2343 | ITSAO4295-14 |
TCMH1423 | Ophiopogon japonicus | 麦冬 | TCMH1423 | ITSAJ4140-14 |
TCMH628 | Glycyrrhiza uralensis | 甘草 | TCMH628 | ITSAM892-14 |
TCMH1080 | Platycodon grandiflorum | 桔梗 | TCMH1080 | ITSAJ4293-14 |
Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
---|---|---|---|---|
TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
Target ID | Target Name |
---|---|
TCMT1170 | Enterobacter cloacae |
TCMT1175 | Human immunodeficiency virus |
TCMT1176 | Streptococcus pneumoniae |
TCMT1178 | Actinomyces viscosus |
TCMT1179 | Escherichia coli ATCC 8739 |
TCMT1181 | Mycobacterium tuberculosis H37Ra |
TCMT1186 | Plasmodium yoelii yoelii |
TCMT1209 | Staphylococcus haemolyticus |
TCMT1212 | Verticillium dahliae |
TCMT1214 | Enterococcus faecium |
TCMT1215 | Pseudomonas aeruginosa PAO1 |
TCMT1218 | Staphylococcus aureus |
TCMT1223 | Staphylococcus epidermidis |
TCMT1224 | Proteus mirabilis |
TCMT1226 | Klebsiella pneumoniae |
TCMT1227 | Streptococcus |
TCMT1229 | Enterococcus faecalis |
TCMT1232 | Pseudomonas aeruginosa |
TCMT1234 | Bacillus coagulans |
TCMT1235 | Clostridium sporogenes |
TCMT1236 | Mycobacterium bovis |
TCMT1237 | Mycobacterium kansasii |
TCMT1238 | Mycobacterium xenopi |
TCMT1239 | Mycobacterium marinum |
TCMT1243 | Aspergillus flavus |
TCMT1246 | Escherichia coli |
TCMT1248 | Hepatitis C virus |
TCMT1249 | Dengue virus 2 |
TCMT1251 | Candida albicans |
TCMT1253 | Penicillium chrysogenum |
TCMT1255 | Human immunodeficiency virus 1 |
TCMT1284 | Penicillium expansum |
TCMT1286 | Bacillus cereus |
TCMT1294 | Human parainfluenza virus 3 |
TCMT1346 | Helicobacter pylori |
TCMT1349 | Helicobacter pylori SS1 |
TCMT1354 | Streptococcus mutans UA159 |
TCMT1412 | Salmonella typhimurium |
TCMT1438 | Plasmodium falciparum |
TCMT1439 | Mycobacterium smegmatis |
TCMT1442 | Leishmania donovani |
TCMT1443 | Leishmania amazonensis |
TCMT1447 | Respiratory syncytial virus |
TCMT1448 | Enterobacter aerogenes |
TCMT1449 | Influenza A virus |
TCMT1450 | Plasmodium falciparum 3D7 |
TCMT1454 | Bacillus subtilis |
TCMT1455 | Mycobacterium tuberculosis H37Rv |
TCMT1457 | Leishmania major |
TCMT1458 | Filobasidiella neoformans |
TCMT1462 | Streptococcus mutans |
TCMT1463 | Mycobacterium tuberculosis |
TCMT1465 | Entamoeba histolytica |
GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
---|---|---|---|
[BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 9.49313 |
[BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.98401 |
[BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.52172 |
[BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA | 7.02809 |
[BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7 | 6.20782 |
[BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.55506 |
[BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.48228 |
[BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.42514 |
[BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.09045 |
[BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FUT7, GBA2, PPARA, TYR, XDH | 5.09045 |
[BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, HSD11B2, HSD17B2, TYR | 5.05545 |
[BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.05545 |
[BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7 | 5.05545 |
[BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, PPARA, TYR | 4.60406 |
[BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.59342 |
[BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, PPARA, TYR | 4.27831 |
[BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, TYR | 4.13328 |
[BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 4.04824 |
[BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, TNKS, TNKS2, XDH | 4.04173 |
[BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.99206 |
[BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, PPARA, TYR | 3.6588 |
[BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2, PPARA | 3.6588 |
[BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.36364 |
[BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.32209 |
[BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 3.26083 |
[BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FUT7, GBA2, HSD17B1, HSD17B2, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.12054 |
[BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 3.08098 |
[BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, PPARA, TYR | 3.00669 |
[BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FUT7, GBA2, HSD11B1, HSD17B2, PPARA, TNKS2, TYR | 2.90443 |
[BP] GO:0009115 | None | AOX1, XDH | 2.85672 |
[BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.71036 |
[BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.69794 |
[BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.51509 |
[BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.50839 |
[BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.50839 |
[BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 2.4823 |
[BP] GO:0046110 | None | AOX1, XDH | 2.43536 |
[BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.43536 |
[BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.41154 |
[BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, GBA2 | 2.38069 |
[BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.37288 |
[BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CSNK2A1, CYP1A2, ESR1, ESRRA, HSD11B2, PPARA | 2.35695 |
[BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.35695 |
[BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, PPARA | 2.35695 |
[BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.34248 |
[BP] GO:1901360 | None | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, TYR, XDH | 2.29684 |
[BP] GO:0009755 | hormone-mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.29018 |
[BP] GO:0070213 | None | TNKS, TNKS2 | 2.21964 |
[BP] GO:0006145 | None | AOX1, XDH | 2.21964 |
[BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.21964 |
[BP] GO:0030522 | intracellular receptor signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.21964 |
[BP] GO:0009611 | response to wounding | ACHE, ADORA3, BCL2, CYP1A1, PPARA | 2.17774 |
[BP] GO:0071704 | organic substance metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 2.15227 |
[BP] GO:0035265 | organ growth | BCL2, CYP19A1, ESR1 | 2.15227 |
[BP] GO:0032228 | regulation of synaptic transmission, GABAergic | ADORA1, CA2, CA7 | 2.07157 |
[BP] GO:0032844 | regulation of homeostatic process | ADORA1, BCL2, CA2, CA7, CDK6, TNKS, TNKS2 | 2.07111 |
[BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, HSD17B2, PPARA, TYR | 2.06242 |
[BP] GO:0003014 | None | ADORA1, AKR1B1, BCL2, HSD11B2 | 2.05128 |
[BP] GO:0043696 | None | CDK6, ESRRB | 2.05128 |
[BP] GO:0043697 | None | CDK6, ESRRB | 2.05128 |
[BP] GO:0048522 | positive regulation of cellular process | ACHE, ADORA1, AKR1B1, BCL2, CA2, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, PPARA, PTPN1, TNKS, TNKS2, XDH | 2.0289 |
[CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.91334 |
[CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.57331 |
[CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 1.41317 |
[CC] GO:0000242 | None | TNKS, TNKS2 | 1.04727 |
[CC] GO:0031233 | None | CA4, F3 | 1.04727 |
[MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, TNKS, TYR, XDH | 9.49313 |
[MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 8.86213 |
[MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 6.39747 |
[MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 6.26226 |
[MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.84753 |
[MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 5.68827 |
[MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 5.05545 |
[MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.77825 |
[MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, TNKS | 4.59342 |
[MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.47345 |
[MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.47345 |
[MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.10787 |
[MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 4.0997 |
[MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.0997 |
[MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.94011 |
[MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.88332 |
[MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.78446 |
[MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.77662 |
[MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.46062 |
[MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.30979 |
[MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 3.26083 |
[MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, HSD17B1, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.23705 |
[MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7 | 3.17432 |
[MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 3.13915 |
[MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.11671 |
[MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 3.05245 |
[MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.85672 |
[MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.85672 |
[MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.85672 |
[MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.39909 |
[MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.21964 |
[MF] GO:0030284 | estrogen receptor activity | ESR1, ESR2 | 2.05128 |
[MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, HSD11B2, HSD17B1, PPARA | 2.01121 |
KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
---|---|---|
Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.8908 |
Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA14 | 10.754 |
Metabolic pathways_Homo sapiens_hsa01100 | AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 6.077 |
Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 6.0595 |
Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.7464 |
Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.7693 |
Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.6354 |
Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.5795 |
Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.9274 |
MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, CDC25B | 1.862 |
Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.8801 |
Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.9274 |
Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.0934 |
Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.5124 |
Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.3931 |
Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.8801 |
Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.4053 |
Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.3924 |
Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.9197 |
AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | BCL2, F3 | 1.2316 |
Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.3087 |
Estrogen signaling pathway_Homo sapiens_hsa04915 | ESR1, ESR2 | 1.2316 |
Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.1878 |
NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.2633 |
Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.1878 |
Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2 | 1.0267 |
Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 1.0692 |
Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.1136 |
Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.991 |
cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.9606 |
Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.8861 |
cAMP signaling pathway_Homo sapiens_hsa04024 | ADORA1, PPARA | 0.8861 |
Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.7256 |
PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.688 |
Pathways in cancer_Homo sapiens_hsa05200 | CDK6, BCL2 | 0.6515 |
Glioma_Homo sapiens_hsa05214 | CDK6 | 0.7003 |
Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.7254 |
Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.7003 |
Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.7003 |
Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | ADORA1 | 0.7254 |
Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.6578 |
Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.6515 |
Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6979 |
Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.7003 |
Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.7003 |
Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.6515 |
Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6979 |
Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.6556 |
Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6578 |
Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.7003 |
Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.5751 |
Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.6515 |
Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.608 |
Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6515 |
Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.5751 |
p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.7003 |
HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.6496 |
Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.6071 |
Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5751 |
Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.608 |
Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.753 |
Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6515 |
Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5751 |
Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5751 |
Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.5253 |
Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.5622 |
Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5751 |
Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.5646 |
PPAR signaling pathway_Homo sapiens_hsa03320 | PPARA | 0.7003 |
Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.7003 |
Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.5163 |
MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.4132 |
Proteoglycans in cancer_Homo sapiens_hsa05205 | ESR1 | 0.4845 |
Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.4845 |
Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.4845 |
Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.5071 |
Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6855 |
Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.5163 |
Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6724 |
Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.7373 |
Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.753 |
Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.753 |
Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.753 |
Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.8002 |
Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.3902 |
Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8861 |
Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8861 |
Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8861 |
Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8918 |
Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8881 |
Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 1.0094 |
Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0743 |
Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.3087 |